Drug Profile
Teriparatide biosimilar - Shanghai Fudan-Zhangjiang Bio-Pharmaceutical
Alternative Names: Recombinant human parathyroid hormone 1-34 - Shanghai Fudan-Zhangjiang Bio-Pharmaceutical; rhPTH1-34 - Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLatest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator Shanghai Fudan-Zhangjiang Bio-Pharmaceutical
- Class Diagnostic agents; Osteoporosis therapies; Peptide hormones; Skin disorder therapies
- Mechanism of Action Parathyroid hormone replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Osteoporosis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Osteoporosis in China (SC)
- 14 May 2015 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical plans to submit a phase II application for Osteoporosis to Chinese SFDA in second half of 2015
- 24 Mar 2015 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical completes a phase I trial in Osteoporosis in China